Bristol-Myers Squibb Company (BMY) Presents at Leerink Partners 2025 Global Healthcare Conference (Transcript)Seeking Alpha • 03/12/25
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.PRNewsWire • 03/11/25
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million DealBenzinga • 03/11/25
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers SquibbBusiness Wire • 03/11/25
Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait?Zacks Investment Research • 03/10/25
Recession Could Be Coming: 5 Strong Buy High-Yield Dividend Stocks That Will Still Outperform24/7 Wall Street • 03/10/25
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic ArthritisBusiness Wire • 03/08/25
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular CarcinomaBusiness Wire • 03/07/25
Bristol-Myers Squibb Company (BMY) Presents at 45th Annual TD Cowen Health Care Conference (Transcript)Seeking Alpha • 03/04/25
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers SquibbAccesswire • 03/04/25
The Artificial Intelligence Party Over for Now? Safe 4%+ High-Yield Dividend Blue Chips Are On Sale24/7 Wall Street • 02/28/25
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closingPRNewsWire • 02/20/25
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung CancerBusiness Wire • 02/19/25
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque PsoriasisBusiness Wire • 02/16/25